AAAAAA

   
Results: 1-18 |
Results: 18
PATIENTS WITH ISOLATED TRISOMY-8 IN ACUTE MYELOID-LEUKEMIA ARE NOT CURED WITH CYTARABINE-BASED CHEMOTHERAPY - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461
Authors: BYRD JC LAWRENCE D ARTHUR DC PETTENATI MJ TANTRAVAHI R QUMSIYEH M STAMBERG J DAVEY FR SCHIFFER CA BLOOMFIELD CD
Citation: Jc. Byrd et al., PATIENTS WITH ISOLATED TRISOMY-8 IN ACUTE MYELOID-LEUKEMIA ARE NOT CURED WITH CYTARABINE-BASED CHEMOTHERAPY - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461, Clinical cancer research, 4(5), 1998, pp. 1235-1241
PATIENTS WITH ISOLATED TRISOMY-8 IN ACUTE MYELOID-LEUKEMIA ARE NOT CURED WITH CYTARABINE-BASED CHEMOTHERAPY - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461
Authors: BYRD JC LAWRENCE D ARTHUR DC PETTENATI MJ TANTRAVAHI R QUMSIYEH M STAMBERG J DAVEY FR SCHIFFER CA BLOOMFIELD CD
Citation: Jc. Byrd et al., PATIENTS WITH ISOLATED TRISOMY-8 IN ACUTE MYELOID-LEUKEMIA ARE NOT CURED WITH CYTARABINE-BASED CHEMOTHERAPY - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461, Clinical cancer research, 4(5), 1998, pp. 1235-1241
FREQUENCY OF PROLONGED REMISSION DURATION AFTER HIGH-DOSE CYTARABINE INTENSIFICATION IN ACUTE MYELOID-LEUKEMIA VARIES BY CYTOGENETIC SUBTYPE
Authors: BLOOMFIELD CD LAWRENCE D BYRD JC CARROLL A PETTENATI MJ TANTRAVAHI R PATIL SR DAVEY FR BERG DT SCHIFFER CA ARTHUR DC MAYER RJ
Citation: Cd. Bloomfield et al., FREQUENCY OF PROLONGED REMISSION DURATION AFTER HIGH-DOSE CYTARABINE INTENSIFICATION IN ACUTE MYELOID-LEUKEMIA VARIES BY CYTOGENETIC SUBTYPE, Cancer research, 58(18), 1998, pp. 4173-4179
PREDICTIVE VALUE OF CLONALITY ASSAYS IN PATIENTS WITH NON-HODGKINS-LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANT - A SINGLE INSTITUTION STUDY
Authors: MACHPASCUAL S LEGARE RD LU D KROON M NEUBERG D TANTRAVAHI R STONE RM FREEDMAN AS NADLER LM GRIBBEN JG GILLILAND DG
Citation: S. Machpascual et al., PREDICTIVE VALUE OF CLONALITY ASSAYS IN PATIENTS WITH NON-HODGKINS-LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANT - A SINGLE INSTITUTION STUDY, Blood, 91(12), 1998, pp. 4496-4503
SECONDARY CYTOGENETIC CHANGES IN ACUTE PROMYELOCYTIC LEUKEMIA - PROGNOSTIC IMPORTANCE IN PATIENTS TREATED WITH CHEMOTHERAPY ALONE AND ASSOCIATION WITH THE INTRON-3 BREAKPOINT OF THE PML GENE - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: SLACK JL ARTHUR DC LAWRENCE D MROZEK K MAYER RJ DAVEY FR TANTRAVAHI R PETTENATI MJ BIGNER S CARROLL AJ RAO KW SCHIFFER CA BLOOMFIELD CD
Citation: Jl. Slack et al., SECONDARY CYTOGENETIC CHANGES IN ACUTE PROMYELOCYTIC LEUKEMIA - PROGNOSTIC IMPORTANCE IN PATIENTS TREATED WITH CHEMOTHERAPY ALONE AND ASSOCIATION WITH THE INTRON-3 BREAKPOINT OF THE PML GENE - A CANCER AND LEUKEMIA GROUP-B STUDY, Journal of clinical oncology, 15(5), 1997, pp. 1786-1795
EXTRAMEDULLARY LEUKEMIA ADVERSELY AFFECTS HEMATOLOGIC COMPLETE REMISSION RATE AND OVERALL SURVIVAL IN PATIENTS WITH T(8-21)(Q22-Q22) - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461
Authors: BYRD JC WEISS RB ARTHUR DC LAWRENCE D BAER MR DAVEY F TRIKHA ES CARROLL AJ TANTRAVAHI R QUMSIYEH M PATIL SR MOORE JO MAYER RJ SCHIFFER CA BLOOMFIELD CD
Citation: Jc. Byrd et al., EXTRAMEDULLARY LEUKEMIA ADVERSELY AFFECTS HEMATOLOGIC COMPLETE REMISSION RATE AND OVERALL SURVIVAL IN PATIENTS WITH T(8-21)(Q22-Q22) - RESULTS FROM CANCER AND LEUKEMIA GROUP-B-8461, Journal of clinical oncology, 15(2), 1997, pp. 466-475
PREDICTION OF THERAPY-RELATED ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR LYMPHOMA
Authors: LEGARE RD GRIBBEN JG MARAGH M HERMANOWSKIVOSATKA A ROACH S TANTRAVAHI R NADLER LM GILLILAND DG
Citation: Rd. Legare et al., PREDICTION OF THERAPY-RELATED ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR LYMPHOMA, American journal of hematology, 56(1), 1997, pp. 45-51
MOLECULAR CHARACTERIZATION OF A TISSUE-SPECIFIC PROTEIN-TYROSINE-PHOSPHATASE (PTP) AND PUTATIVE TUMOR-SUPPRESSOR WHICH IS DOWN-REGULATED INHIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMAS (DLB-CLS)
Authors: AGUIAR RCT YAKUSHIJIN Y FREEMAN G LI J TANTRAVAHI R SHIPP MA
Citation: Rct. Aguiar et al., MOLECULAR CHARACTERIZATION OF A TISSUE-SPECIFIC PROTEIN-TYROSINE-PHOSPHATASE (PTP) AND PUTATIVE TUMOR-SUPPRESSOR WHICH IS DOWN-REGULATED INHIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMAS (DLB-CLS), Blood, 90(10), 1997, pp. 2185-2185
MURINE MYELOID LEUKEMIC-CELLS WITH DISRUPTED MYB LOCI SHOW SPLICING ANOMALIES THAT ACCOUNT FOR HETEROGENEOUS SIZES IN MYB PROTEINS
Authors: TANTRAVAHI R DUDEK H PATEL G REDDY EP
Citation: R. Tantravahi et al., MURINE MYELOID LEUKEMIC-CELLS WITH DISRUPTED MYB LOCI SHOW SPLICING ANOMALIES THAT ACCOUNT FOR HETEROGENEOUS SIZES IN MYB PROTEINS, Oncogene, 13(6), 1996, pp. 1187-1196
TRANSCRIPTIONAL ACTIVATION POTENTIAL OF NORMAL AND TUMOR-ASSOCIATED MYB ISOFORMS DOES NOT CORRELATE WITH THEIR ABILITY TO BLOCK GCSF-INDUCED TERMINAL DIFFERENTIATION OF MURINE MYELOID PRECURSOR CELLS
Authors: PATEL G TANTRAVAHI R OH IH REDDY EP
Citation: G. Patel et al., TRANSCRIPTIONAL ACTIVATION POTENTIAL OF NORMAL AND TUMOR-ASSOCIATED MYB ISOFORMS DOES NOT CORRELATE WITH THEIR ABILITY TO BLOCK GCSF-INDUCED TERMINAL DIFFERENTIATION OF MURINE MYELOID PRECURSOR CELLS, Oncogene, 13(6), 1996, pp. 1197-1208
CHARACTERIZATION OF A CELL-LINE, NKL, DERIVED FROM AN AGGRESSIVE HUMAN NATURAL-KILLER-CELL LEUKEMIA
Authors: ROBERTSON MJ COCHRAN KJ CAMERON C LE JM TANTRAVAHI R RITZ J
Citation: Mj. Robertson et al., CHARACTERIZATION OF A CELL-LINE, NKL, DERIVED FROM AN AGGRESSIVE HUMAN NATURAL-KILLER-CELL LEUKEMIA, Experimental hematology, 24(3), 1996, pp. 406-415
TEL AML-1 DIMERIZES AND IS ASSOCIATED WITH A FAVORABLE OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA/
Authors: MCLEAN TW RINGOLD S NEUBERG D STEGMAIER K TANTRAVAHI R RITZ J KOEFFLER HP TAKEUCHI S JANSSEN JWG SERIU T BARTRAM CR SALLAN SE GILLILAND DG GOLUB TR
Citation: Tw. Mclean et al., TEL AML-1 DIMERIZES AND IS ASSOCIATED WITH A FAVORABLE OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA/, Blood, 88(11), 1996, pp. 4252-4258
DER(16)T(1-16) IS A NONRANDOM SECONDARY CHROMOSOME ABERRATION IN MANYTYPES OF HUMAN NEOPLASIA, INCLUDING MYXOID LIPOSARCOMA, RHABDOMYOSARCOMA AND PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: MROZEK K ARTHUR DC KARAKOUSIS CP KODURU PRK LEBEAU MM PETTENATI MJ TANTRAVAHI R MROZEK E PEREZMESA C RAO UNM FRANKEL SR DAVEY FR BLOOMFIELD CD
Citation: K. Mrozek et al., DER(16)T(1-16) IS A NONRANDOM SECONDARY CHROMOSOME ABERRATION IN MANYTYPES OF HUMAN NEOPLASIA, INCLUDING MYXOID LIPOSARCOMA, RHABDOMYOSARCOMA AND PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA, International journal of oncology, 6(3), 1995, pp. 531-538
MOLECULAR-CLONING OF HUMAN PAXILLIN, A FOCAL ADHESION PROTEIN PHOSPHORYLATED BY P210(BCR ABL)/
Authors: SALGIA R LI JL LO SH BRUNKHORST B KANSAS GS SOBHANY ES SUN YP PISICK E HALLEK M ERNST T TANTRAVAHI R CHEN LB GRIFFIN JD
Citation: R. Salgia et al., MOLECULAR-CLONING OF HUMAN PAXILLIN, A FOCAL ADHESION PROTEIN PHOSPHORYLATED BY P210(BCR ABL)/, The Journal of biological chemistry, 270(10), 1995, pp. 5039-5047
A SYNDROME OF LYMPHOBLASTIC LYMPHOMA, EOSINOPHILIA, AND MYELOID HYPERPLASIA MALIGNANCY ASSOCIATED WITH T(8-13) (P11-Q11) - DESCRIPTION OF ADISTINCTIVE CLINICOPATHOLOGICAL ENTITY
Authors: INHORN RC ASTER JC ROACH SA SLAPAK CA SOIFFER R TANTRAVAHI R STONE RM
Citation: Rc. Inhorn et al., A SYNDROME OF LYMPHOBLASTIC LYMPHOMA, EOSINOPHILIA, AND MYELOID HYPERPLASIA MALIGNANCY ASSOCIATED WITH T(8-13) (P11-Q11) - DESCRIPTION OF ADISTINCTIVE CLINICOPATHOLOGICAL ENTITY, Blood, 85(7), 1995, pp. 1881-1887
CLONALITY ANALYSIS OF CHILDHOOD ALL IN REMISSION - NO EVIDENCE OF CLONAL HEMATOPOIESIS
Authors: BUSQUE L ILARIA R TANTRAVAHI R WEINSTEIN H GILLILAND DG
Citation: L. Busque et al., CLONALITY ANALYSIS OF CHILDHOOD ALL IN REMISSION - NO EVIDENCE OF CLONAL HEMATOPOIESIS, Leukemia research, 18(2), 1994, pp. 71-77
HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT AFTER TREATMENT OF STABLE-PHASE CHRONIC MYELOGENOUS LEUKEMIA WITH CONTINUOUS-INFUSION OF LOW-DOSE CYTARABINE
Authors: ROBERTSON MJ TANTRAVAHI R GRIFFIN JD CANELLOS GP CANNISTRA SA
Citation: Mj. Robertson et al., HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT AFTER TREATMENT OF STABLE-PHASE CHRONIC MYELOGENOUS LEUKEMIA WITH CONTINUOUS-INFUSION OF LOW-DOSE CYTARABINE, American journal of hematology, 43(2), 1993, pp. 95-102
PROLONGED SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT INTERFERON-ALPHA-2B IN PATIENTS WITH PREVIOUSLY UNTREATED PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA - EFFECT ON REMISSION DURATION AND SURVIVAL - CANCER AND LEUKEMIA GROUP-B STUDY-8583
Authors: OZER H GEORGE SL SCHIFFER CA RAO K RAO PN WURSTERHILL DH ARTHUR DD POWELL B GOTTLIEB A PETERSON BA RAI K TESTA JR LEBEAU M TANTRAVAHI R BLOOMFIELD CD
Citation: H. Ozer et al., PROLONGED SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT INTERFERON-ALPHA-2B IN PATIENTS WITH PREVIOUSLY UNTREATED PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA - EFFECT ON REMISSION DURATION AND SURVIVAL - CANCER AND LEUKEMIA GROUP-B STUDY-8583, Blood, 82(10), 1993, pp. 2975-2984
Risultati: 1-18 |